| Code | CSB-RA015007MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of ocrelizumab (Ocrevus®), targeting MS4A1 (CD20)—a B-cell surface antigen expressed from late pre-B cells through mature and memory B cells, but generally absent on terminally differentiated plasma cells. As a lineage-restricted marker, CD20 enables precise interrogation of B-cell contributions to immune regulation and inflammation, including antibody-independent roles of B cells (e.g., antigen presentation and cytokine networks) that are highly relevant to immune-mediated disease research.
Ocrelizumab is a humanized anti-CD20 IgG1 monoclonal antibody that selectively depletes CD20⁺ B cells, with mechanisms reported to include ADCC/ADCP, complement-dependent cytotoxicity, and apoptosis (with a profile often described as relatively ADCC-dominant among anti-CD20 antibodies). This biosimilar provides the antibody component alone, enabling researchers to study CD20 target engagement, Fc-effector–driven B-cell depletion mechanisms, and downstream immunologic consequences in controlled experimental systems—supporting assay development and mechanistic studies aligned with multiple sclerosis (relapsing and primary progressive forms) and broader B-cell–mediated immunobiology.
There are currently no reviews for this product.